Currently, several HER2-directed therapies such as the HER2-directed antibodies trastuzumab (T) and pertuzumab (P), tyrosine kinase inhibitors, and antibody–drug conjugates are available for the treatment of patients with HER2-positive (HER2+) metastatic BC [4]. This evidence concerns the gene ERBB2 and breast cancer.